Merck KGaA and Pfizer’s Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20

 Merck KGaA and Pfizer’s Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20

Merck KGaA and Pfizer’s Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20

Shots:

  • The P-II study involves assessing of Bavencio in 15 women (median age 34yrs.) with GTT that are resistant to mono-CT. All patients had progressed on treatment with MTX; one patient had progressed on actinomycin-D. while patients received Bavencio until hCG levels returned to normal, followed by 3 additional cycles
  • Results: 8/15 patients had no sign of disease relapse @29mos. follow-up. & hCG levels returned to normal and have been maintained, if disease has not relapsed @12mos. & monitoring of hCG has concluded, the patient is considered cured, Bavencio showed resistance in the remaining  7 patients (47%), requiring CT with actinomycin-D/ polychemotherapy with/out surgery
  • The study suggested that Bavencio may work as a potential therapy for GTT patients. The study is the first study exploring use of immunotherapy in patients with GTT

Click here ­to­ read full press release/ article | Ref: ASCO | Image: Pfizer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post